Data for Riociguat presented at the CHEST 2012 Annual Meeting
October 20 - 25, 2012
Atlanta, Georgia, USA
Findings from two Phase III studies evaluating Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) and in pulmonary arterial hypertension (PAH) were presented in the late-breaking abstracts session on October 23, 2012 from 4:30 – 5:45 p.m. EDT at the 2012 American College of Chest Physicians (ACCP) annual meeting (CHEST 2012) in Atlanta, USA.
On this occasion we hosted a conference call for investors and analysts on October 24, 2012 at approx. 1:00 p.m. CEST (11:00 a.m. GMT).
Oktober 24, 2012: Investor Conference Call on Riociguat
Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations
|Transcript||Download PDF collect (131 KB)|